Cost-Effectiveness Analysis of Lu-177-PSMA-617
Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant [...]
Lu-177-PSMA-617 approved by FDA for prostate cancer patients
Novartis has obtained US Food and Drug Administration (FDA) marketing [...]
Novel Radioligand Proven Superior for Metastatic Prostate Cancer
Novel Radioligand Therapy Proven Superior for Metastatic Prostate Cancer Patients [...]